Emerging optical and nuclear medicine imaging methods in rheumatoid arthritis

Nature Reviews Rheumatology

Volumn 8, Issue 12, 2012, Pages 719-728

  Mountz, James M ^a   Alavi, Abass ^b   Mountz, John D ^c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^c University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; CARBON 11; CHOLINE C 11; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; IODINE 123; IODINE 124; LIPOCORTIN 5; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; RITUXIMAB; TECHNETIUM 99M;

BIOCHEMISTRY; CELL ACTIVITY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; EARLY INTERVENTION; HUMAN; INDIVIDUALIZATION; INFRARED PHOTOGRAPHY; LIGHT SCATTERING; MEDICAL DECISION MAKING; MOLECULAR IMAGING; NEAR INFRARED MOLECULAR IMAGING; NON INVASIVE MEASUREMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGICAL ANATOMY; PATHOPHYSIOLOGY; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; RHEUMATOID ARTHRITIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT RESPONSE;

ARTHRITIS, RHEUMATOID; EARLY DIAGNOSIS; HUMANS; JOINTS; MAGNETIC RESONANCE IMAGING; MOLECULAR IMAGING; POSITRON-EMISSION TOMOGRAPHY; THERMOGRAPHY;

EID: 84870679622     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2012.148     Document Type: Review

References (73)

1. Brennan, P. et al. A simple algorithm to predict the development of radiological erosions in patients with early rheumatoid arthritis: Prospective cohort study. BMJ 313, 471-476 (1996).
2. Klarlund, M. et al. Magnetic resonance imaging, radiography, and scintigraphy of the finger joints: One year follow up of patients with early arthritis. Ann. Rheum. Dis. 59, 521-528 (2000).
3. McQueen, F. M. et al. Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals progression of erosions despite clinical improvement. Ann. Rheum. Dis. 58, 156-163 (1999).
4. McQueen, F. M. et al. What is the fate of erosions in early rheumatoid arthritis? Tracking individual lesions using x rays and magnetic resonance imaging over the first two years of disease. Ann. Rheum. Dis. 60, 859-868 (2001).
5. Kokkonen, H. et al. Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis. Arthritis Rheum. 62, 383-391 (2010).
6. Davila, L. & Ranganathan, P. Pharmacogenetics: Implications for therapy in rheumatic diseases. Nat. Rev. Rheumatol. 7, 537-550 (2011).
7. Devereaux, M. D., Parr, G. R., Thomas, D. P. & Hazleman, B. L. Disease activity indexes in rheumatoid arthritis; a prospective, comparative study with thermography. Ann. Rheum. Dis. 44, 434-437 (1985).
8. Spadling, S. J. et al. Three-dimensional and thermal surface imaging produces reliable measures of joint shape and temperature: A potential tool for quantifying arthritis. Arthritis Res. Ther. 10, R10 (2008).
9. Fischer, T. et al. Detection of rheumatoid arthritis using non-specific contrast enhanced fluorescence imaging. Acad. Radiol. 17, 375-381 (2010).
10. Prapavat, V. et al. The development of a finger joint phantom for the optical stimulation of early inflammatory rheumatic changes [German]. Biomed. Tech. (Berl.) 42, 319-326 (1997).
11. Scheel, A. K. et al. Assessment of proximal finger joint inflammation in patients with rheumatoid arthritis, using a novel laser-based imaging technique. Arthritis Rheum. 46, 1177-1184 (2002).
12. Hielscher, A. H. et al. Sagittal laser optical tomography for imaging of rheumatoid finger joints. Phys. Med. Biol. 49, 1147-1163 (2004).
13. Scheel, A. K. et al. First clinical evaluation of sagittal laser optical tomography for detection of synovitis in arthritic finger joints. Ann. Rheum. Dis. 64, 239-245 (2005).
14. Klose, C. D., Klose, A. D., Netz, U., Beuthan, J. & Hielscher, A. H. Multiparameter classifications of optical tomographic images. J. Biomed. Opt. 13, 050503 (2008).
15. Aswathy, R. G., Yoshida, Y., Maekawa, T. & Kumar, D. S. Near-infrared quantum dots for deep tissue imaging. Anal. Bioanal. Chem. 397, 1417-1435 (2010).
16. Canvin, J. M. et al. Infrared spectroscopy: Shedding light on synovitis in patients with rheumatoid arthritis. Rheumatology (Oxford) 42, 76-82 (2003).
17. Fischer, T. et al. Assessment of unspecific near-infrared dyes in laser-induced fluorescence imaging of experimental arthritis. Acad. Radiol. 13, 4-13 (2006).
18. Hansch, A. et al. In vivo imaging of experimental arthritis with near-infrared fluorescence. Arthritis Rheum. 50, 961-967 (2004).
19. Hansch, A. et al. Diagnosis of arthritis using near-infrared fluorochrome Cy5.5. Invest. Radiol. 39, 626-632 (2004).
20. Chen, W. T., Mahmood, U., Weissleder, R. & Tung, C. H. Arthritis imaging using a near-infrared fluorescence folate-targeted probe. Arthritis Res. Ther. 7, R310-R317 (2005).
21. Simon, G. H. et al. Optical imaging of experimental arthritis using allogeneic leukocytes labeled with a near-infrared fluorescent probe. Eur. J. Nucl. Med. Mol. Imaging 33, 998-1006 (2006).
22. Pogue, B. W. Near-infrared characterization of disease via vascular permeability probes. Acad. Radiol. 13, 1-3 (2006).
23. Rengel, Y., Ospelt, C. & Gay, S. Proteinases in the joint: Clinical relevance of proteinases in joint destruction. Arthritis Res. Ther. 9, 221 (2007).
24. Ntziachristos, V., Tung, C. H., Bremer, C. & Weissleder, R. Fluorescence molecular tomography resolves protease activity in vivo. Nat. Med. 8, 757-760 (2002).
25. Wunder, A., Tung, C. H., Müller-Ladner, U., Weissleder, R. & Mahmood, U. In vivo imaging of protease activity in arthritis: A novel approach for monitoring treatment response. Arthritis Rheum. 50, 2459-2465 (2004).
26. Li, J. et al. Treatment of arthritis by macrophage depletion and immunomodulation: Testing an apoptosis-mediated therapy in a humanized death receptor mouse model. Arthritis Rheum. 64, 1098-1109 (2012).
27. Post, A. M. et al. Imaging cell death with radiolabeled annexin V in an experimental model of rheumatoid arthritis. J. Nucl. Med. 43, 1359-1365 (2002).
28. Blankenberg, F. G. In vivo detection of apoptosis. J. Nucl. Med. 49 (Suppl. 2), 81S-95S (2008).
29. Edgington, L. E. et al. Noninvasive optical imaging of apoptosis by caspase-targeted activity-based probes. Nat. Med. 15, 967-973 (2009).
30. McBride, H. J. Nuclear imaging of autoimmunity: Focus on IBD and RA. Autoimmunity 43, 539-549 (2010).
31. Gotthardt, M., Bleeker-Rovers, C. P., Boerman, O. C. & Oyen, W. J. Imaging of inflammation by PET, conventional scintigraphy, and other imaging techniques. J. Nucl. Med. 51, 1937-1949 (2010).
32. Sokoloff, L. et al. The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: Theory, procedure, and normal values in the conscious and anesthetized albino rat. J. Neurochem. 28, 897-916 (1977).
33. Hawkins, R. A. et al. PET cancer evaluations with FDG. J. Nucl. Med. 32, 1555-1558 (1991).
34. Ju, J. H. et al. Visualization and localization of rheumatoid knee synovitis with FDG-PET/CT images. Clin. Rheumatol. 27 (Suppl. 2), S39-S41 (2008).
35. Matsui, T. et al. Inflammatory cytokines and hypoxia contribute to 18F-FDG uptake by cells involved in pannus formation in rheumatoid arthritis. J. Nucl. Med. 50, 920-926 (2009).
36. Basu, S. et al. Novel quantitative techniques for assessing regional and global function and structure based on modern imaging modalities: Implications for normal variation, aging and diseased states. Semin. Nucl. Med. 37, 223-239 (2007).
37. Torigian, D. A. et al. Feasibility and performance of novel software to quantify metabolically active volumes and 3D partial volume corrected SUV and metabolic volumetric products of spinal bone marrow metastases on 18F FDG PET/CT. Hell. J. Nucl. Med. 14, 8-14 (2011).
38. Basu, S. & Alavi, A. Unparalleled contribution of 18F-FDG PET to medicine over 3 decades. J. Nucl. Med. 49, 17N-21N, 37N (2008).
39. Basu, S. et al. Functional imaging of inflammatory diseases using nuclear medicine techniques. Semin. Nucl. Med. 39, 124-145 (2009).
40. Vogel, W. V., van Riel, P. L. & Oyen, W. J. FDG-PET/CT can visualise the extent of inflammation in rheumatoid arthritis of the tarsus. Eur. J. Nucl. Med. Mol. Imaging 34, 439 (2007).
41. Brenner, W. 18F-FDG PET in rheumatoid arthritis: There still is a long way to go. J. Nucl. Med. 45, 927-929 (2004).
42. Fonseca, A. et al. 18F-FDG PET imaging of rheumatoid articular and extraarticular synovitis. J. Clin. Rheumatol. 14, 307 (2008).
43. Kubota, K. et al. Whole-body FDG-PET/CT on rheumatoid arthritis of large joints. Ann. Nucl. Med. 23, 783-791 (2009).
44. Lin, P. W., Liu, R. S., Liou, T. H., Pan, L. C. & Chen, C. H. Correlation between joint [F-18] FDG PET uptake and synovial TNF-α concentration: A study with two rabbit models of acute inflammatory arthritis. Appl. Radiat. Isot. 65, 1221-1226 (2007).
45. Mountz, J. D. et al. Molecular imaging: New applications for biochemistry. J. Cell. Biochem. Suppl. 39, 162-171 (2002).
46. Roivainen, A. et al. Use of positron emission tomography with methyl 11C choline and 2 18F fluoro 2 deoxy D glucose in comparison with magnetic resonance imaging for the assessment of inflammatory proliferation of synovium. Arthritis Rheum. 48, 3077-3084 (2003).
47. Polisson, R. P. et al. Use of magnetic resonance imaging and positron emission tomography in the assessment of synovial volume and glucose metabolism in patients with rheumatoid arthritis. Arthritis Rheum. 38, 819-825 (1995).
48. Carey, K. et al. Evolving role of FDG PET imaging in assessing joint disorders: A systematic review. Eur. J. Nucl. Med. Mol. Imaging 38, 1939-1955 (2011).
49. Beckers, C. et al. Assessment of disease activity in rheumatoid arthritis with 18F-FDG PET. J. Nucl. Med. 45, 956-964 (2004).
50. Beckers, C. et al. 18F-FDG PET imaging of rheumatoid knee synovitis correlates with dynamic magnetic resonance and sonographic assessments as well as with the serum level of metalloproteinase-3. Eur. J Nucl. Med. Mol. Imaging 33, 275-280 (2006).
51. Palmer, W. E. et al. Quantification of inflammation in the wrist with gadolinium-enhanced MR imaging and PET with 2-[F-18] fluoro 2 deoxy D-glucose. Radiology 196, 647-655 (1995).
52. Goerres, G. W. et al. F-18 FDG whole-body PET for the assessment of disease activity in patients with rheumatoid arthritis. Clin. Nucl. Med. 31, 386-390 (2006).
53. Szekanecz, Z., Besenyei, T., Paragh, G. & Koch,A. E. New insights in synovial angiogenesis. Joint Bone Spine 77, 13-19 (2010).
54. Friedlander, M. et al. Involvement of integrins αvβ3 and αvβ5 in ocular neovascular diseases. Proc. Natl Acad. Sci. USA 93, 9764-9769 (1996).
55. Sipkins, D. A. et al. Detection of tumor angiogenesis in vivo by αvβ3-targeted magnetic resonance imaging. Nat. Med. 4, 623-626 (1998).
56. Nakamura, I., Duong le, T., Rodan, S. B. & Rodan, G. A. Involvement of αvβ3 integrins in osteoclast function. J. Bone Miner. Metab. 25, 337-344 (2007).
57. Wilder, R. L. Integrin αvβ3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases. Ann. Rheum. Dis. 61 (Suppl. 2), ii96-ii99 (2002).
58. Beer, A. J. et al. PET-based human dosimetry of 18F galacto RGD, a new radiotracer for imaging αvβ3 expression. J. Nucl. Med. 47, 763-769 (2006).
59. Niu, G. & Chen, X. PET Imaging of Angiogenesis. PET Clin. 4, 17-38 (2009).
60. Leung, K. 4-[18F]Fluorobenzoyl Phe Ala Leu Gly Glu Ala-NH2. Molecular Imaging and Contrast Agent Database [online], http://www.ncbi.nlm.nih.gov/books/ NBK82507/pdf/FBA FALGEA 18F.pdf (2011).
61. Zheleznyak, A. et al. Integrin αvβ3 as a PET imaging biomarker for osteoclast number in mouse models of negative and positive osteoclast regulation. Mol. Imaging Biol. http://dx.doi.org/10.1007/s11307 011 0512-4.
62. Martens, C. L. et al. Peptides which bind to E-selectin and block neutrophil adhesion. J. Biol. Chem. 270, 21129-21136 (1995).
63. Gaál, J. et al. 99mTc-HMPAO labelled leukocyte scintigraphy in patients with rheumatoid arthritis: A comparison with disease activity. Nucl. Med. Commun. 23, 39-46 (2002).
64. Barrera, P. et al. Radiolabelled interleukin 1 receptor antagonist for detection of synovitis in patients with rheumatoid arthritis. Rheumatology (Oxford) 39, 870-874 (2000).
65. Roimicher, L. et al. 99mTc anti TNF-α scintigraphy in RA: A comparison pilot study with MRI and clinical examination. Rheumatology (Oxford) 50, 2044-2050 (2011).
66. Gent, Y. Y. et al. Macrophage positron emission tomography imaging as a biomarker for preclinical rheumatoid arthritis: Findings of a prospective pilot study. Arthritis Rheum. 64, 62-66 (2012).
67. van der Laken, C. J. et al. Noninvasive imaging of macrophages in rheumatoid synovitis using 11C-(R)-PK11195 and positron emission tomography. Arthritis Rheum. 58, 3350-3355 (2008).
68. Schrigten, D. et al. A new generation of radiofluorinated pyrimidine-2, 4, 6-triones as MMP-targeted radiotracers for positron emission tomography. J. Med. Chem. 55, 223-232 (2012).
69. Beyer, T. et al. A combined PET/CT scanner for clinical oncology. J. Nucl. Med. 41, 1369-1379 (2000).
70. Tran, L. et al. CD20 antigen imaging with 124I-rituximab PET/CT in patients with rheumatoid arthritis. Hum. Antibodies 20, 29-35 (2011).
71. Delso, G. et al. Performance measurements of the Siemens mMR integrated whole-body PET/MR scanner. J. Nucl. Med. 52, 1914-1922 (2011).
72. Borrero, C. G., Mountz, J. M. & Mountz, J. D. Emerging MRI methods in rheumatoid arthritis. Nat. Rev. Rheumatol. 7, 85-95 (2011).
73. Kropholler, M. A. et al. Quantification of (R)-[11C]PK11195 binding in rheumatoid arthritis. Eur. J. Nucl. Med. Mol. Imaging 36, 624-631 (2009).